The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.

MLA

Wang, Xishu, et al. “The Efficacy and Safety of Radiofrequency Ablation Combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Real-World Study.” BMC Cancer, vol. 24, no. 1, Aug. 2024, p. 1036. EBSCOhost, https://doi.org/10.1186/s12885-024-12779-5.

APA

Wang, X., Sun, X., Lei, Y., Fang, L., Wang, Y., Feng, K., & Xia, F. (2024). The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study. BMC Cancer, 24(1), 1036. https://doi.org/10.1186/s12885-024-12779-5

Chicago

Wang, Xishu, Ximin Sun, Yongrong Lei, Lingyan Fang, Yuedi Wang, Kai Feng, and Feng Xia. 2024. “The Efficacy and Safety of Radiofrequency Ablation Combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Real-World Study.” BMC Cancer 24 (1): 1036. doi:10.1186/s12885-024-12779-5.